Shell Asset Management CO Vertex Pharmaceuticals Inc Transaction History

Shell Asset Management CO

$2.26 Billion
Q1 2024

A detailed history of Shell Asset Management CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Shell Asset Management CO holds 17,462 shares of VRTX stock, worth $8.27 Million. This represents 0.32% of its overall portfolio holdings.

Number of Shares

17,462

Previous 16,151 8.12%

Holding current value

$8.27 Million

Previous $6.57 Million 11.06%

% of portfolio

0.32%

Previous 0.3%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$407.69 - $446.08 $534,481 - $584,810	1,311 Added 8.12%	17,462 $7.3 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $966,231 - $1.16 Million	-2,817 Reduced 14.85%	16,151 $6.57 Million
Q3 2023 Nov 08, 2023	SELL	$338.18 - $362.46 $71,694 - $76,841	-212 Reduced 1.11%	18,968 $6.6 Million
Q2 2023 Jul 28, 2023	BUY	$314.42 - $351.91 $288,951 - $323,405	919 Added 5.03%	19,180 $6.75 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $11,612 - $13,247	-41 Reduced 0.22%	18,261 $5.75 Million

Q4 2022 Feb 07, 2023	SELL	$285.76 - $321.48 $1.58 Million - $1.78 Million	-5,523 Reduced 23.18%	18,302 $5.29 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $1.47 Million - $1.64 Million	-5,375 Reduced 18.41%	23,825 $6.9 Million
Q2 2022 Aug 09, 2022	SELL	$234.96 - $292.55 $897,782 - $1.12 Million	-3,821 Reduced 11.57%	29,200 $8.23 Million
Q1 2022 May 04, 2022	BUY	$221.42 - $260.97 $925,978 - $1.09 Million	4,182 Added 14.5%	33,021 $8.62 Million
Q4 2021 Feb 09, 2022	SELL	$177.01 - $223.45 $1.42 Million - $1.79 Million	-8,012 Reduced 21.74%	28,839 $6.33 Million
Q3 2021 Nov 04, 2021	SELL	$181.39 - $202.99 $3.23 Million - $3.61 Million	-17,808 Reduced 32.58%	36,851 $6.68 Million
Q2 2021 Aug 12, 2021	SELL	$187.49 - $221.1 $1.45 Million - $1.7 Million	-7,709 Reduced 12.36%	54,659 $11 Million
Q1 2021 May 10, 2021	SELL	$207.02 - $241.31 $3.09 Million - $3.6 Million	-14,921 Reduced 19.31%	62,368 $13.4 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $5.25 Million - $7 Million	25,367 Added 48.86%	77,289 $18.3 Million
Q3 2020 Nov 13, 2020	SELL	$255.65 - $303.1 $82,319 - $97,598	-322 Reduced 0.62%	51,922 $14.1 Million
Q2 2020 Aug 10, 2020	BUY	$225.48 - $295.8 $8.13 Million - $10.7 Million	36,049 Added 222.59%	52,244 $15.2 Million
Q1 2020 May 11, 2020	SELL	$199.77 - $247.81 $361,783 - $448,783	-1,811 Reduced 10.06%	16,195 $3.85 Million
Q4 2019 Feb 13, 2020	SELL	$166.71 - $223.91 $84,521 - $113,522	-507 Reduced 2.74%	18,006 $3.94 Million
Q3 2019 Nov 12, 2019	SELL	$166.23 - $187.09 $405,268 - $456,125	-2,438 Reduced 11.64%	18,513 $3.14 Million
Q2 2019 Aug 12, 2019	BUY	$164.61 - $190.37 $158,684 - $183,516	964 Added 4.82%	20,951 $3.84 Million
Q1 2019 May 09, 2019	BUY	$163.73 - $194.7 $215,141 - $255,835	1,314 Added 7.04%	19,987 $3.68 Million
Q4 2018 Feb 13, 2019	SELL	$151.91 - $192.21 $768,664 - $972,582	-5,060 Reduced 21.32%	18,673 $3.09 Million
Q3 2018 Nov 13, 2018	SELL	$167.73 - $192.74 $178,967 - $205,653	-1,067 Reduced 4.3%	23,733 $4.57 Million
Q2 2018 Aug 10, 2018	BUY	$145.72 - $169.96 $192,787 - $224,857	1,323 Added 5.64%	24,800 $4.22 Million
Q1 2018 May 14, 2018	SELL	$151.6 - $177.13 $182,981 - $213,795	-1,207 Reduced 4.89%	23,477 $3.83 Million
Q4 2017 Feb 09, 2018	BUY	$137.28 - $155.55 $431,333 - $488,738	3,142 Added 14.59%	24,684 $3.7 Million
Q3 2017 Oct 20, 2017	SELL	$148.13 - $162.24 $3.69 Million - $4.04 Million	-24,911 Reduced 53.63%	21,542 $3.28 Million
Q3 2017 Oct 18, 2017	BUY	$148.13 - $162.24 $6.88 Million - $7.54 Million	46,453	46,453 $5.22 Million

Others Institutions Holding VRTX

# of Institutions

1,624

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.

Account

Shell Asset Management CO Vertex Pharmaceuticals Inc Transaction History